Table 2.
Censored median TTPbr and OS (with 95% confidence interval) in months from date of first RT to brain
| No ipilimumab | Ipilimumab | P-value | |
|---|---|---|---|
| TTPbr | |||
| All patients | 3.3 (1.5–6.3) | 2.7 (1.5–6.0) | 0.55 |
| WBRT | 3.3 (1.4–6.3) | 2.7 (1.0–8.2) | 0.72 |
| SRS | 2.6 (not estimable1) | 2.6 (1.2 to not estimable2) | 0.95 |
| OS | |||
| All patients | 5.3 (4.0–7.6) | 18.3 (8.1–25.5) | 0.002 |
| WBRT | 5.3 (4.3–7.6) | 3.1 (1.9 to not estimable2) | 0.60 |
| SRS | 4.0 (3.2–14.6) | 19.9 (15.9 to not estimable2) | 0.009 |
TTPbr, time to progression in the brain; OS, overall survival; RT, radiation therapy; WBRT, whole brain radiation therapy; SRS, stereotactic radiosurgery.
1
The 95% confidence interval for the median survival time could not be determined because there were only five patients in this cell.
2
The upper limit of the 95% confidence interval for the median survival time could not be determined because the estimated upper confidence limit for the survival function for this group never falls below 0.5 [19].